Large-scale manufacturing of base-edited chimeric antigen receptor T cells

Overview
This study develops a protocol for manufacturing base-edited CAR-T cells using circular RNA (circRNA) to reduce costs and improve stability compared to linear mRNA. Large-scale production of PD-1 deficient CAR-T cells was achieved using 100M and six-well G-Rex® vessels, demonstrating scalability.
What this paper found
Circular RNA encoding the cytosine base editor BE4max disrupted PD-1 in primary human T cells more efficiently than linear mRNA, and supported manufacture of a clinical-scale dose of base-edited anti-CD19 CAR T cells. CircRNA was produced by Anabaena permuted intron-exon self-splicing with a mean circularization efficiency of 68.7%, and gave higher BE4max protein levels despite similar RNA decay, cutting the RNA requirement about 8-fold. In a semi-closed process, CD4+/CD8+ cells selected on the CliniMACS Prodigy were activated, nucleofected on day 2, transduced with an anti-CD19 CAR on day 3, and expanded 2- to 3-fold to about 1 × 10^8 cells by day 9. On-target C-to-T conversion reached 86% with 0.25 µg and 100% with 1.00 µg circRNA per 1 × 10^6 cells.
Note: The authors state that off-target events were not assessed in this study because the PD-1 guide RNA sequence had been validated previously.
In summary, we demonstrate the application of circRNA for base editing in primary T cells and prove that it is superior to linear mRNA. — Rosie Woodruff, Farhaan Parekh, Katarina Lamb, Leila Mekkaoui, Christopher Allen, Katerina Smetanova, Jasmine Huang, Alex Williams, Gerardo Santiago Toledo, Koki Lilova, Claire Roddie, James Sillibourne, Martin Pule, Molecular Therapy Methods & Clinical Development
Study details
- Authors
- Rosie Woodruff, Farhaan Parekh, Katarina Lamb, Leila Mekkaoui, Christopher Allen, Katerina Smetanova, Jasmine Huang, Alex Williams, Gerardo Santiago Toledo, Koki Lilova, Claire Roddie, James Sillibourne, Martin Pule
- Institution
- Autolus Therapeutics, London, UK · Imperial College London, London, UK · Department of Haematology, Cancer Institute, London, UK
- Journal
- Molecular Therapy Methods & Clinical Development
- Year
- 2023
- G-Rex® model(s)
- G-Rex®100M, G-Rex®6 Well Plate
- Cell type(s)
- CAR T Cells, T-Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
How G-Rex® was used
In the large-scale process, CD4+/CD8+ T cells selected from leukapheresate on the CliniMACS Prodigy were activated with GMP-grade TransAct and cultured in a 100M G-Rex® (RU81100). After nucleofection with BE4max circRNA and the PD-1 or non-targeting sgRNA on day 2, the base-edited T cells were cultured in a six-well G-Rex® (80240M) and left to recover overnight before lentiviral transduction with the anti-CD19 CAR on day 3. Starting from about 5 × 10^6 nucleofected cells, the cultures expanded roughly 2- to 3-fold to reach about 1 × 10^8 CAR T cells by day 9, when they were cryopreserved.
Note: Transduction itself was performed outside the gas-permeable vessels, in RetroNectin-coated 100-mL differentiation bags seeded at 1 × 10^6 cells/mL with lentiviral supernatant.
Explore related
Full citation
Woodruff R, Parekh F, Lamb K, et al. Large-scale manufacturing of base-edited chimeric antigen receptor T cells. Mol Ther Methods Clin Dev. 2023;31:101123.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.